Asia Pacific Flowable Hemostats Market

The Asia Pacific flowable hemostats market is expected to grow from US$ 176.64 million in 2022 to US$ 275.19 million by 2028. It is estimated record a CAGR of 7.7% from 2022 to 2028.

Increasing Number of Hospitals and Surgical Centers Fuels Asia Pacific Flowable Hemostats Market

Injuries are still a significant concern to public health. An increase in global trauma and accident cases is a major driver of the Asia Pacific flowable hemostats market. According to World Health Organization (WHO), annually approximately 1.3 million people cut short their lives because of a road traffic crash. Between 20 to 50 million people suffer non-fatal injuries, with many incurring a disability because of their injury. Globally, hemorrhage or excessive bleeding is responsible for over one-third of pre-hospital deaths and over 40% of deaths within the first 24 hours. The number of surgeries is rising owing to the increasing musculoskeletal disorders related with sports, occupational injuries, and age-related dysfunction. However, a substantial proportion of health gains are lost owing to sports-related injuries. The National Library of Medicine report states China as a large base of patients agonizing traumatic brain injury (TBI) compared to other countries, making this condition a major public health concern. Thus, increasing number of injuries and surgical procedures are responsible for the high adoption of flowable hemostats, thereby driving the market's growth during the forecast period.

Asia Pacific Flowable Hemostats Market Overview

The Asia Pacific flowable hemostats market is segmented into China, Japan, India, South Korea, Australia, and the rest of Asia Pacific. The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of market in the Asia Pacific region is expected to grow at a faster pace owing to investments made in the infrastructure development of the healthcare sector, rising number of surgical procedures, growing emphasis on providing superior surgical outcomes, and favorable regulatory approvals. China holds a considerable share in the Asia Pacific flowable hemostats market. The market is expected to grow owing to the growing emphasis on providing superior surgical care, and the growing demand for modern healthcare instruments. The rise in the prevalence of bleeding disorders has paved the way for the design, development, and piloting of flowable hemostats. According to a Hemophilia Treatment Center Collaboration Network of China (HTCCNC) study, HTCCNC identified 17,779 patients with Hemophilia A from 2007 to 2019. Patients were predominantly male (99.99%), and 28.3% had a known family history of hemophilia. Among patients with lab-measured disease severity (N = 13,116), 6,519 had severe HA (49.7%), 4,788 had moderate HA (36.5%), and 1,809 had mild HA (13.8%). Thus, rising incidences of hemophilia will increase the demand for flowable hemostats during the forecast period.

Asia Pacific Flowable Hemostats Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Flowable Hemostats Market Segmentation

The Asia Pacific flowable hemostats market is segmented into material, product, application, end user, and country.

Based on material, the Asia Pacific flowable hemostats market is bifurcated into bovine gelatin and porcine gelatin. The bovine gelatin segment held a larger share of the Asia Pacific flowable hemostats market in 2022.

In terms of product, the Asia Pacific flowable hemostats market is segmented into combination hemostats, passive hemostats, and active hemostats. The combination hemostats segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

Based on application, the Asia Pacific flowable hemostats market is categorized into general surgery, cardiac surgery, vascular surgery, orthopedic surgery, neuro and spine surgery, and others. The general surgery segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

Based on end user, the Asia Pacific flowable hemostats market is segmented into hospitals and clinics, ambulatory surgery centers, and others. The hospitals and clinics segment held the largest share of the Asia Pacific flowable hemostats market in 2022.

By country, the Asia Pacific flowable hemostats market is categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific flowable hemostats market in 2022. 

Baxter International Inc, Ethicon (Johnson & Johnson), Pfizer Inc, Teleflex Incorporated, 3-D Matrix Medical Technology, and Aegis Lifesciences are some of the leading companies operating in the Asia Pacific flowable hemostats market. 

Asia Pacific Flowable Hemostats Market Strategic Insights

Asia Pacific Flowable Hemostats Market Segmentation Analysis

Asia Pacific Flowable Hemostats Market Report Highlights

Asia Pacific Flowable Hemostats Report Scope

Asia Pacific Flowable Hemostats Market Country and Regional Insights